NS-229

About NS Pharma

NS Pharma is a private, clinical-stage biotech subsidiary of Japan's Nippon Shinyaku, headquartered in Paramus, New Jersey. The company is dedicated to advancing therapies for rare diseases, with a pipeline centered on exon-skipping oligonucleotides for Duchenne Muscular Dystrophy and a JAK1 inhibitor for eosinophilic granulomatosis with polyangiitis (EGPA). Its lead asset, brogidirsen (NS-089/NCNP-02), has reported multi-year clinical data, positioning the company in the competitive DMD landscape, while its platform extends to cell therapy research. NS Pharma operates as a strategic R&D arm, likely funded by its parent company, with a patient-centric mission driven by innovative science.

Therapeutic Areas